# US 2020/0368393 A1 · Biological Formulations and Methods for Treating Cardiac Tissue and Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368393 A1
- Document ID: US20200368393A1
- Status: Published application
- Kind: A1
- Application number: 16/990,519
- Filed: 2020-08-11
- Published: 2020-11-26
- Earliest claimed: 2011-12-16
- Assignees: CorMatrix Cardiovascular, Inc.
- Applicants: CorMatrix Cardiovascular, Inc.
- Inventors: Robert G. Matheny
- Web page: https://patentgrep.com/patent/US20200368393A1

## CPC

- A61L 27/3633: {Extracellular matrix [ECM]}
- A61F 2/0095: {Packages or dispensers for prostheses or other implants (for intraocular lenses A61F2/1691; for dental surgery A61C19/02)}
- A61F 2/06: Blood vessels
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61L 27/34: Macromolecular materials
- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61L 27/507: {for artificial blood vessels (apparatus for applying cells on a blood vessel prosthesis A61F2/062)}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/58: Materials at least partially resorbable by the body
- A61F 2210/0004: bioabsorbable
- A61F 2250/0067: Means for introducing or releasing pharmaceutical products into the body
- A61L 2300/406: Antibiotics
- A61L 2300/414: Growth factors
- A61L 2300/426: Immunomodulating agents, i.e. cytokines, interleukins, interferons
- A61L 2300/62: Encapsulated active agents, e.g. emulsified droplets
- A61L 2300/626: Liposomes, micelles, vesicles
- A61L 2430/20: for reconstruction of the heart, e.g. heart valves
- A61M 5/178: Syringes
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Methods for treating damaged cardiac tissue by delivering biological formulations proximate the pericardial space of a mammalian heart that (i) enhance and supplement the properties provided by the GATA6+ macrophages in the serous fluid and/or (ii) restore, enhance and supplement the properties provided by the GATA6+ macrophages when the pericardial space is breached and the serous fluid is expelled.

## Claims

### Claim 1

A method for treating damaged cardiac tissue, comprising:
providing a biological formulation comprising Wharton's jelly from a mammalian source,
said biological formulation being adapted to induce recruitment and proliferation of endogenous GATA6+ macrophages, when said biological formulation is delivered to a target site disposed in a pericardial space of a subject's heart, said pericardial space comprising serous fluid,
delivering said biological formulation to said target site in said subject's heart, said target site also being disposed proximate a damaged tissue region,
wherein, after said delivery of said biological formulation to said target site, said biological formulation induces recruitment and proliferation of first endogenous GATA6+ macrophages disposed proximate said damaged tissue site, whereby said biological formulation induces modulated healing of damaged tissue in said damaged tissue region.

### Claim 2 (depends on 1)

The method of claim 1, wherein said pericardial space is disposed between an outer surface of a visceral layer of a serous pericardium and an inner surface of a parietal layer of said serous pericardium.

### Claim 3 (depends on 1)

The method of claim 1, wherein said modulated healing comprises inflammation modulation of said damaged tissue and induced neovascularization of said damaged tissue, stem cell proliferation and, thereby, positive remodeling of said damaged tissue, and regeneration of new tissue and tissue structures with site specific structural and functional properties.

### Claim 4 (depends on 1)

The method of claim 1, wherein said biological formulation comprises at least one supplemental biologically active agent.

### Claim 5 (depends on 4)

The method of claim 4, wherein said biologically active agent comprises a growth factor selected from the group consisting of basic fibroblast growth factor (bFGF), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF).

### Claim 6 (depends on 4)

The method of claim 4, wherein said biologically active agent comprises a cytokine.

### Claim 7 (depends on 6)

The method of claim 6, wherein said cytokine comprises an interleukin selected from the group consisting of interleukin-10 (IL-10), interleukin-1α (IL-1α) and interleukin-8 (IL-8)

### Claim 8 (depends on 1)

The method of claim 1, wherein said biological formulation comprises at least one pharmacological agent.

### Claim 9 (depends on 8)

The method of claim 8, wherein said pharmacological agent comprises an antibiotic agent.

### Claim 10 (depends on 8)

The method of claim 8, wherein said antibiotic agent is selected from the group consisting of vancomycin and gentamicin.

### Claim 11

A method for treating damaged cardiac tissue, comprising:
providing an exosome augmented biological formulation comprising Wharton's jelly from a mammalian source and a plurality of exogenous exosomes,
said exosome augmented biological formulation being adapted to induce recruitment and proliferation of endogenous GATA6+ macrophages contained in serous fluid and modulate at least one paracrine process associated with said GATA6+ macrophages, when said exosome augmented biological formulation is delivered to a target site disposed in a pericardial space of a subject's heart, said pericardial space comprising serous fluid,
delivering said exosome augmented biological formulation to said target site in said subject's heart, said target site also being disposed proximate a damaged tissue region,
wherein, after said delivery of said exosome augmented biological formulation to said target site, said exosome augmented biological formulation induces recruitment and proliferation of first endogenous GATA6+ macrophages disposed proximate said damaged tissue site and modulates at least a first paracrine process associated with said GATA6+ macrophages, whereby said exosome augmented biological formulation induces modulated healing of damaged tissue in said damaged tissue region.

### Claim 12 (depends on 11)

The method of claim 11, wherein said first paracrine process comprises inducing endogenous cell populations proximate said damaged tissue region to produce increased concentrations of bioavailable growth factors compared to native concentrations of said bioavailable growth factors.

### Claim 13 (depends on 11)

The method of claim 11, wherein said first paracrine process comprises inducing endogenous cardiac fibroblasts proximate said damaged tissue region to increase expression and, thereby, synthesis of hepatocyte growth factor (HGF).

### Claim 14 (depends on 11)

The method of claim 11, wherein said first paracrine process comprises inducing endogenous epicardial progenitor cells (EPCs) proximate said damaged tissue region to transition from an inactive state to an active state and undergo epithelial-to-mesenchymal transition.

### Claim 15 (depends on 11)

The method of claim 11, wherein said first paracrine process comprises inducing a transition of a microenvironment of said damaged tissue site from an acute inflammatory state to a wound healing state characterized by the transition of circulating monocyte-derived macrophages from a M1 subtype to a M2 subtype.

### Claim 16 (depends on 11)

The method of claim 11, wherein said modulated healing comprises inflammation modulation of said damaged tissue and induced neovascularization, stem cell proliferation and, thereby, positive remodeling of said damaged tissue, and regeneration of new tissue and tissue structures with site specific structural and functional properties.

### Claim 17 (depends on 11)

The method of claim 11, wherein said plurality of exosomes are derived from at least one cell source selected from the group consisting of cardiac progenitor cells (CPCs), valvular interstitial cells (VICs), amniotic fluid-derived mesenchymal stem cells (af-MSCs), embryonic-like stem cells, placental cells, umbilical cord-derived mesenchymal stem cells (uc-MSCs), Wharton's jelly-derived mesenchymal stem cells (wj-MSCs), amniotic membrane-derived mesenchymal stem cells (am-MSCs), adipose tissue-derived mesenchymal stem cells (at-MSCs) and bone marrow-derived mesenchymal stem cells (bm-MSCs).

### Claim 18 (depends on 11)

The method of claim 11, wherein said plurality of exosomes are derived from at least one mammalian tissue source selected from the group consisting of small intestine tissue, large intestine tissue, stomach tissue, lung tissue, liver tissue, kidney tissue, pancreas tissue, placental tissue, cardiac tissue, bladder tissue, prostate tissue, and any fetal tissue from any mammalian organ.

### Claim 19 (depends on 11)

The method of claim 11, wherein said plurality of exosomes are derived from mammalian fluid, said mammalian fluid comprising mammalian fluid selected from the group consisting of blood, amniotic fluid, lymphatic fluid, interstitial fluid, pleural fluid, peritoneal fluid, pericardial fluid and cerebrospinal fluid.

### Claim 20 (depends on 11)

The method of claim 11, wherein said exosome augmented biological formulation comprises at least one supplemental biologically active agent.

### Claim 21 (depends on 20)

The method of claim 20, wherein said biologically active agent comprises a growth factor selected from the group consisting of basic fibroblast growth factor (bFGF), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF).

### Claim 22 (depends on 20)

The method of claim 20, wherein said biologically active agent comprises a cytokine.

### Claim 23 (depends on 23)

The method of claim 23, wherein said cytokine comprises an interleukin selected from the group consisting of interleukin-10 (IL-10), interleukin-1α (IL-1α) and interleukin-8 (IL-8)

### Claim 24 (depends on 8)

The method of claim 8, wherein said exosome augmented biological formulation comprises an antibiotic agent selected from the group consisting of vancomycin and gentamicin.
